BACKGROUND: Outcomes in patients with acute promyelocytic leukemia (APL) have improved; however, a significant number of patients still relapse despite receiving all-trans-retinoic acid (ATRA) and arsenic-based therapies. PATIENTS AND METHODS: Outcomes of patients with relapsed APL who were treated at our institution (1980-2010) and who received HCT were compared with those who received chemotherapy (CT) only. RESULTS: Among 40 patients, 24 received HCT (autologous [auto] HCT, 7; allogeneic [allo] HCT, 14; both, 3); 16 received CT only. The median age at diagnosis was 36 years (range, 13-50 years), 31 years (range, 16-58 years), and 44 years (range, 24-79 years) for the auto-HCT, allo-HCT, and CT groups, respectively. Ten (100%) patients who received auto-HCT and 12 (71%) who received allo-HCT were in complete remission at the time of the HCT. The median follow-ups in the auto-HCT, allo-HCT, and CT groups were 74 months (range, 26-135 months), 118 months (range, 28-284 months), and 122 months (range, 32-216 months), respectively. Transplantation-related mortality (1 year) after auto-HCT and allo-HCT were 10% and 29%, respectively. The 7-year event-free survival after auto-HCT and allo-HCT was 68.6% and 40.6%, respectively (P = .45). The 7-year overall survival was 85.7%, 49.4%, and 40% in the auto-HCT, allo-HCT, and CT groups, respectively (P = .48). CONCLUSION: Both auto-HCT and allo-HCT are associated with durable remission and prolonged survival. All 3 strategies (auto-HCT, allo-HCT, CT) were found to be feasible in the relapsed APL setting and result in long-term disease control in selected patients. In this retrospective analysis, overall survival for patients who received HCT was not significantly better than patients who received CT only, but a trend toward better outcomes was seen in patients who underwent auto-HCT, although not statistically significant. Published by Elsevier Inc.
BACKGROUND: Outcomes in patients with acute promyelocytic leukemia (APL) have improved; however, a significant number of patients still relapse despite receiving all-trans-retinoic acid (ATRA) and arsenic-based therapies. PATIENTS AND METHODS: Outcomes of patients with relapsed APL who were treated at our institution (1980-2010) and who received HCT were compared with those who received chemotherapy (CT) only. RESULTS: Among 40 patients, 24 received HCT (autologous [auto] HCT, 7; allogeneic [allo] HCT, 14; both, 3); 16 received CT only. The median age at diagnosis was 36 years (range, 13-50 years), 31 years (range, 16-58 years), and 44 years (range, 24-79 years) for the auto-HCT, allo-HCT, and CT groups, respectively. Ten (100%) patients who received auto-HCT and 12 (71%) who received allo-HCT were in complete remission at the time of the HCT. The median follow-ups in the auto-HCT, allo-HCT, and CT groups were 74 months (range, 26-135 months), 118 months (range, 28-284 months), and 122 months (range, 32-216 months), respectively. Transplantation-related mortality (1 year) after auto-HCT and allo-HCT were 10% and 29%, respectively. The 7-year event-free survival after auto-HCT and allo-HCT was 68.6% and 40.6%, respectively (P = .45). The 7-year overall survival was 85.7%, 49.4%, and 40% in the auto-HCT, allo-HCT, and CT groups, respectively (P = .48). CONCLUSION: Both auto-HCT and allo-HCT are associated with durable remission and prolonged survival. All 3 strategies (auto-HCT, allo-HCT, CT) were found to be feasible in the relapsed APL setting and result in long-term disease control in selected patients. In this retrospective analysis, overall survival for patients who received HCT was not significantly better than patients who received CT only, but a trend toward better outcomes was seen in patients who underwent auto-HCT, although not statistically significant. Published by Elsevier Inc.
Authors: S de Botton; A Fawaz; S Chevret; H Dombret; X Thomas; M Sanz; A Guerci; J San Miguel; J de la Serna; A M Stoppa; O Reman; A Stamatoulas; M Fey; J Y Cahn; J J Sotto; J H Bourhis; A Parry; C Chomienne; L Degos; P Fenaux Journal: J Clin Oncol Date: 2004-11-08 Impact factor: 44.544
Authors: M A Sanz; M Labopin; N-C Gorin; J de la Rubia; W Arcese; G Meloni; A Bacigalupo; P Alessandrino; E Carreras; A Iriondo; N Novitzky; P Jacobs; G Bandini; F Lo-Coco; F Frassoni; V Rocha Journal: Bone Marrow Transplant Date: 2007-02-26 Impact factor: 5.483
Authors: C A Linker; K Owzar; B Powell; D Hurd; L E Damon; L E Archer; R A Larson Journal: Bone Marrow Transplant Date: 2009-03-16 Impact factor: 5.483
Authors: E Lengfelder; F Lo-Coco; L Ades; P Montesinos; D Grimwade; B Kishore; S M Ramadan; M Pagoni; M Breccia; A J G Huerta; A M Nloga; J D González-Sanmiguel; A Schmidt; J-F Lambert; S Lehmann; E Di Bona; B Cassinat; W-K Hofmann; D Görlich; M-C Sauerland; P Fenaux; M Sanz Journal: Leukemia Date: 2015-01-28 Impact factor: 11.528
Authors: M D Seftel; M J Barnett; S Couban; B Leber; J Storring; W Assaily; B Fuerth; A Christofides; A C Schuh Journal: Curr Oncol Date: 2014-10 Impact factor: 3.677
Authors: Satiro N De Oliveira; Roy L Kao; Andrew Pham; LaMarr Taylor Smith; Pamela Kempert; Theodore B Moore Journal: Pediatr Transplant Date: 2016-02-05